Budesonide-formoterol efficacy
Pro Research Analysisby 
Searched over 200M research papers for "budesonide-formoterol efficacy"
Budesonide-Formoterol Efficacy in COPD: Exacerbation Reduction and Lung Function Improvement
Budesonide-formoterol, a combination of an inhaled corticosteroid and a long-acting beta-agonist, has shown significant efficacy in managing chronic obstructive pulmonary disease (COPD). Multiple studies demonstrate that this combination reduces the rate of severe exacerbations compared to placebo and monotherapies. For example, budesonide-formoterol reduced severe exacerbations by 24% versus placebo and 23% versus formoterol alone, while also improving forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) over 12 months 1358. These improvements were consistent across different dosages and delivery devices, with both 320/9 µg and 160/9 µg doses showing benefits in exacerbation reduction and lung function 358.
Budesonide-Formoterol in Asthma: Superior Control and Reduced Exacerbations
In patients with mild-to-moderate asthma, budesonide-formoterol used as both maintenance and reliever therapy led to greater improvements in morning PEF and a 54% lower risk of severe exacerbations compared to higher-dose budesonide plus as-needed terbutaline . Another large trial found that as-needed budesonide-formoterol was more effective at preventing severe exacerbations than maintenance low-dose budesonide plus as-needed terbutaline, supporting its use as an alternative regimen for mild asthma . These studies also noted fewer hospitalizations and a lower steroid burden with budesonide-formoterol 26.
Efficacy in Bronchiolitis Obliterans and Non-Cystic Fibrosis Bronchiectasis
Budesonide-formoterol has also been evaluated in other respiratory conditions. In bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation, budesonide-formoterol significantly improved FEV1 compared to placebo, with the effect maintained over six months . However, increasing the dose from 160/4.5 µg to 320/9 µg did not yield significant additional improvements in FEV1 or symptom scores . In non-cystic fibrosis bronchiectasis, medium-dose budesonide-formoterol was more effective and had fewer side effects than high-dose budesonide alone, improving symptoms and quality of life .
Safety Profile of Budesonide-Formoterol
Across studies, budesonide-formoterol was generally well tolerated, with a safety profile similar to its individual components and placebo 1358. The incidence of pneumonia and other serious adverse events was low and comparable across treatment groups, with no significant increase observed in the active treatment arms 3589.
Conclusion
Budesonide-formoterol is effective in reducing exacerbations, improving lung function, and enhancing quality of life in patients with COPD, asthma, BOS, and non-cystic fibrosis bronchiectasis. Its benefits are seen across various dosages and disease severities, with a favorable safety profile. These findings support its use as a key therapy in the management of chronic respiratory diseases.
Sources and full results
Most relevant research papers on this topic